ライフサイエンスコーパス: radioiodine

1 ed therapeutics alone or in combination with radioiodine.

2 sis for a personalized approach for adjuvant radioiodine.

3 atment of patients with hyperthyroidism with radioiodine.

4 a from a thyroid cancer patient treated with radioiodine.

5 stered intramuscularly prior to testing with radioiodine.

6 prescription of the administered activity of radioiodine.

7 toxicity to normal tissues from therapeutic radioiodine.

8 efficacy of the subsequent ablation dose of radioiodine.

9 er the ability to treat prostate cancer with radioiodine.

10 d for long-term vigilance in those receiving radioiodine.

11 step toward therapy of prostate cancer with radioiodine.

12 , oncocytic thyroid carcinoma rarely absorbs radioiodine.

13 etween 0.5 and 120 h after administration of radioiodine.

14 deposition patterns between radiocesium and radioiodine.

15 ine-avid and can be effectively treated with radioiodine.

16 scintigraphic images reflects uptake of free radioiodine.

17 It is not known whether low-dose radioiodine (1.1 GBq [30 mCi]) is as effective as high-d

18 blation with postoperative administration of radioiodine (1.1 GBq) after injections of recombinant hu

19 Labelling with radioiodine ((123,125)I) was achieved in 55 +/- 12% radi

20 The radioiodines 123I, 124I, 125I and 131I were accommodated

21 passively extract soil solution spiked with radioiodine ((129)I(-) and (129)IO(3)(-)) to monitor sho

22 se of recombinant human thyrotropin) and two radioiodine ((131)I) doses (i.e., administered activitie

23 the benefit and minimizing the morbidity of radioiodine ((131)I) therapy.

24 these, 59 patients had negative findings on radioiodine (131I) whole-body scintigraphy (WBS).

25 1 GBq [30 mCi]) is as effective as high-dose radioiodine (3.7 GBq [100 mCi]) for treating patients wi

26 ) in patients receiving higher activities of radioiodine (~3.7 GBq).

27 Of the 8 patients treated with radioiodine, 5 had confirmed partial responses and 3 had

28 t neck dissection, followed by postoperative radioiodine ablation and appropriate thyroid-stimulating

29 otropin and low-dose (1.1 GBq) postoperative radioiodine ablation may be sufficient for the managemen

30 to accumulate iodide provides the basis for radioiodine ablation of differentiated thyroid cancers a

31 Thyrogen-assisted diagnosis and radioiodine ablation of thyroid remnant provide a reliab

32 and function is affected after high-activity radioiodine ablation therapy in patients with DTC.

33 a 185-MBq (5 mCi) dose of (131)I 72 h before radioiodine ablation without concern for thyroid stunnin

34 with postoperative radioiodine (also called radioiodine ablation) after total thyroidectomy.

35 After total thyroidectomy followed by radioiodine ablation, 61 consecutive patients with eleva

36 After thyroidectomy and radioiodine ablation, thyroglobulin becomes a sensitive

37 Therefore, we investigated radioiodine accumulation and therapeutic effectiveness o

38 prostate-specific promoters induces generous radioiodine accumulation in prostate cancer cells that m

39 higher rates (24%) in patients receiving low radioiodine activities (~1.1 GBq) and lower rates (8%-18

40 In the approach of fixed radioiodine activity (3.0 +/- 1.0 GBq), 89% of thyroid r

41 Higher levels of radioiodine activity also were observed in kidney when L

42 Thyroid ablation was assessed 8 months after radioiodine administration by neck ultrasonography and m

43 ice were treated with a MEK inhibitor before radioiodine administration.

44 ncer can often be treated with postoperative radioiodine (also called radioiodine ablation) after tot

45 cer worldwide can safely avoid postoperative radioiodine and its related hospitalisation and side-eff

46 h water, but in contrast allows placement of radioiodine and the photoactive moieties within the same

47 novirus serotypes 2 and 12 were labeled with radioiodine and then injected into the bloodstreams of m

48 ignificant improvement in tumor retention of radioiodine and tumor:normal tissue ratios was seen when

49 and transgene expression before therapeutic radioiodine application.

50 Using iodine/radioiodine as a surrogate for the radiohalogen (211)At,

51 targeting as a specific method to detect non-radioiodine-avid thyroid cancer in thyroid orthotopic tu

52 , a condition simulating the presence of non-radioiodine-avid thyroid cancer nodules, and high accumu

53 microsomes and uptake of the resultant free radioiodine by Na/I symporters in the gastric mucosa.

54 trial shows that ablation (or postoperative radioiodine) can be avoided for patients with pT1, pT2,

55 Radioiodine capture from nuclear fuel waste and contamin

56 so advances POC as an efficient platform for radioiodine capture in industry.

57 Treatment with levothyroxine and radioiodine contribute alternative cardiovascular functi

58 Higher ex vivo radioiodine counts were noted in the hearts perfused wit

59 The geochemical transport and fate of radioiodine depends largely on its chemical speciation t

60 used on better patient selection and reduced radioiodine doses for remnant ablation.

61 ority trial comparing low-dose and high-dose radioiodine, each in combination with either thyrotropin

62 rapeutic role of VCP inhibitors in enhancing radioiodine effectiveness in radioiodine-refractory thyr

63 ted thyroid cancer or whether the effects of radioiodine (especially at a low dose) are influenced by

64 ne-glycine-aspartic acid peptide ligands and radioiodine, exhibited high-affinity/avidity binding, fa

65 f iodine (I) in soil is critical to evaluate radioiodine exposure and understand soil-to-crop transfe

66 Nevada Test Site (1951-1992) has resulted in radioiodine exposure for nearby populations.

67 Our findings suggest that childhood radioiodine exposure from nuclear testing may be related

68 e is known regarding the effect of childhood radioiodine exposure on subsequent fertility.

69 though the long-term effect of environmental radioiodine exposure on thyroid disease has been well st

70 young patients exposed to the post-Chernobyl radioiodine fallout at very young age and a matched none

71 arcinoma (PTC) among children exposed to the radioiodine fallout has been one of the main consequence

72 We find that radioiodine fallout is actively and efficiently scavenge

73 Additionally, 1 of 12 patients who received radioiodine for differentiated thyroid carcinoma also sh

74 ions of GO in American patients treated with radioiodine for hyperthyroidism.

75 dence and mortality in patients treated with radioiodine for hyperthyroidism.

76 Dissociation of radioiodine from the antibody during metabolism has been

77 es have shown that rapid clearance of excess radioiodine from the body in the euthyroid state with Th

78 ug group, mortality was lower among those in radioiodine group A (HR 0.50, 95% CI 0.29-0.85), but not

79 oiodine with resolved hyperthyroidism group (radioiodine group A), or radioiodine with unresolved hyp

80 e in the antithyroid drug group, 250 were in radioiodine group A, 182 were in radioiodine group B.

81 dence interval [CI], 93.0 to 97.5) in the no-radioiodine group and 95.9% (95% CI, 93.3 to 97.7) in th

82 .50, 95% CI 0.29-0.85), but not for those in radioiodine group B (HR 1.51, 95% CI 0.96-2.37).

83 odine with unresolved hyperthyroidism group (radioiodine group B).

84 250 were in radioiodine group A, 182 were in radioiodine group B.

85 g that required subsequent treatment (in the radioiodine group only), abnormal findings on neck ultra

86 injections of recombinant human thyrotropin (radioiodine group) or to receive no postoperative radioi

87 to receive no postoperative radioiodine (no-radioiodine group).

88 roup and 95.9% (95% CI, 93.3 to 97.7) in the radioiodine group, a difference of -0.3 percentage point

89 Since then, radioiodine has become broadly established clinically fo

90 Radioiodine has been shown to reduce recurrences and imp

91 d synthetic methods for the incorporation of radioiodine have generally involved high temperature rea

92 with papillary thyroid cancer who underwent radioiodine imaging and (18)F-FDG PET/CT after total thy

93 evated serum thyroglobulin and both negative radioiodine imaging and negative (18)F-FDG PET/CT.

94 this paper addresses the role of preablation radioiodine imaging and provides nuclear medicine physic

95 py settings and reviews the impact of fusion radioiodine imaging on staging, risk stratification, and

96 iodide symporter (hNIS), in combination with radioiodine in an orthotopic triple-negative breast canc

97 urs with hypothyroidism stimulates uptake of radioiodine in normal and cancerous thyroid tissues.

98 ARRY-142886) could reverse refractoriness to radioiodine in patients with metastatic thyroid cancer.

99 adioactive plume and the behavior of harmful radioiodine in the atmosphere, long-term precipitation s

100 Analogous to radioiodine in the evaluation of patients with different

101 The elevated levels of radioiodine in the stomach observed in our experiments a

102 via an indirect method attenuated uptake of radioiodine in tissues that express the Na/I symporter w

103 uorous oxidant that can be used to introduce radioiodine into small molecules and proteins and genera

104 tatic thyroid cancers that are refractory to radioiodine (iodine-131) are associated with a poor prog

105 dectomy, the postoperative administration of radioiodine (iodine-131) is controversial in the absence

106 trations to stimulate thyroid tissue so that radioiodine (iodine-131) scanning can be performed.

107 tiated thyroid cancer that was refractory to radioiodine (iodine-131).

108 yperthyroidism with antithyroid drugs alone, radioiodine is increasingly used as first line therapy,

109 ty in those treated for hyperthyroidism with radioiodine is reassuring.

110 Radioiodine is used increasingly as first-line treatment

111 The radioiodine isotope pair (124)I/(131)I is used in a ther

112 e provide a survey of the use of 2 different radioiodine isotopes for targeting the sodium-iodine sym

113 proach also highlights the impact of altered radioiodine kinetics as seen with recombinant human thyr

114 Low renal retention of the radioiodine label creates a precondition for radionuclid

115 We designed a route to prepare the radioiodine-labeled androgen on microscale through treat

116 . administration; intravenously administered radioiodine-labeled asialoEPO bound to neurons within th

117 or to confer residualizing properties on the radioiodine metabolites.

118 euthyroid with either long-term CBZ (n=3) or radioiodine (n=2).

119 in the case of negative (18)F-FDG PET/CT in radioiodine-negative DTC patients with elevated and risi

120 trast-enhanced, full-dose) in 15 consecutive radioiodine-negative DTC patients with elevated and risi

121 Patients who are thyroglobulin-positive but radioiodine-negative or who have antithyroglobulin antib

122 iodine group) or to receive no postoperative radioiodine (no-radioiodine group).

123 t least one positive scan) were treated with radioiodine on the basis of superior scans done after wi

124 Thyroid scintigraphy with either radioiodine or (99m)Tc-pertechnetate is useful to charac

125 remains a choice between antithyroid drugs, radioiodine or surgery.

126 mean age, 16.5 y) were treated with (131)I (radioiodine, or radioactive iodine [RAI]); the median fo

127 is routinely treated with antithyroid drugs, radioiodine, or surgery, but whether the choice of initi

128 us thyrotropin alfa (84.3%) versus high-dose radioiodine plus thyroid hormone withdrawal (87.6%) or h

129 Similar results were found for low-dose radioiodine plus thyrotropin alfa (84.3%) versus high-do

130 roid hormone withdrawal (87.6%) or high-dose radioiodine plus thyrotropin alfa (90.2%).

131 Low-dose radioiodine plus thyrotropin alfa was as effective as hi

132 ACOF-1 and ACOF-1R promising adsorbents for radioiodine pollutants treatment under practical conditi

133 t or accidental events involving exposure to radioiodines, prophylaxis against malignant disease of t

134 t is not clear whether the administration of radioiodine provides any benefit to patients with low-ri

135 id follicular cells, providing the basis for radioiodine (RAI) imaging and therapy of differentiated

136 been exploited for over 75 years in ablative radioiodine (RAI) treatment of thyroid cancer, where its

137 those that are refractory to treatment with radioiodine (RAI), have a high prevalence of BRAF (v-raf

138 wth factor receptor (VEGFR) and approved for radioiodine (RAI)-refractory differentiated thyroid canc

139 Aggressive thyroid carcinoma, including radioiodine refractory (RAIR) differentiated thyroid car

140 r-targeted treatments hold great promise for radioiodine-refractory and surgically inoperable thyroid

141 Patients with radioiodine-refractory cancer have historically had poor

142 ways have been tested in clinical trials for radioiodine-refractory differentiated thyroid cancer (DT

143 Patients with radioiodine-refractory differentiated thyroid cancer (DT

144 rvival (PFS) versus placebo in patients with radioiodine-refractory differentiated thyroid cancer (RR

145 US Food and Drug Administration-approved for radioiodine-refractory differentiated thyroid cancer and

146 tients with metastatic, rapidly progressive, radioiodine-refractory differentiated thyroid cancers.

147 etastatic differentiated thyroid cancer have radioiodine-refractory disease, based on decreased expre

148 Patients with radioiodine-refractory disease, therefore, are not amena

149 al trials of targeted drugs in patients with radioiodine-refractory disease.

150 trial, patients aged 16 years and older with radioiodine-refractory DTC (papillary or follicular and

151 ide a new treatment option for patients with radioiodine-refractory DTC who have no available standar

152 ion of (124)I dosimetry in a patient who had radioiodine-refractory thyroid cancer and who underwent

153 in delineating the molecular pathogenesis of radioiodine-refractory thyroid cancer.

154 rs in enhancing radioiodine effectiveness in radioiodine-refractory thyroid cancer.

155 The onset of radioiodine-refractory thyroid carcinoma (RR-TC) is a ne

156 was noninferior to an ablation strategy with radioiodine regarding the occurrence of functional, stru

157 ospectively assessed a median of 2.5 y after radioiodine remnant ablation (RRA) in 394 consecutive th

158 Radioiodine remnant ablation (RRA) is frequently used af

159 encing and because it cannot be labeled with radioiodine, requiring radiolabeling of the peptide liga

160 progressive, locally advanced or metastatic, radioiodine-resistant differentiated thyroid cancer with

161 dioiodine retention with all of the adducts; radioiodine retention at 45 h was up to 86% greater in c

162 ssing experiments showed marked increases in radioiodine retention with all of the adducts; radioiodi

163 nts with thyroid cancer underwent whole-body radioiodine scanning by two techniques: first after rece

164 of the 127 patients had positive whole-body radioiodine scans by one or both techniques.

165 that were not detected by the corresponding radioiodine scans.

166 aging studies, including CT, ultrasound, and radioiodine scintigraphy (RIS).

167 ing by application of SPECT/CT technology to radioiodine scintigraphy in both diagnostic and post-the

168 molecular markers, postoperative diagnostic radioiodine scintigraphy, and thyroglobulin levels.

169 disease and early definitive treatment with radioiodine should be offered to patients who are unlike

170 east lesions on sestamibi scans, bone scans, radioiodine studies, as well as PET studies using fluori

171 Patients staged pN0 received less radioiodine than patients staged pN1 (median 30 vs 100 m

172 , a novel approach for labeling the PNA with radioiodine that avoided solubility issues and poor labe

173 ts with thyroid cancer that is refractory to radioiodine; the effectiveness may be greater in patient

174 ent study, concerning a total of 206 patient radioiodine therapies carried out at King Faisal Special

175 In high-activity radioiodine therapies for differentiated thyroid cancer,

176 Adjuvant radioiodine therapy (RITh) for differentiated thyroid ca

177 des dietary iodine supplementation, surgery, radioiodine therapy (to decrease thyroid size), and mini

178 Early side effects of radioiodine therapy (typically mild pain in the thyroid)

179 One patient had received no previous radioiodine therapy and another withdrew consent before

180 ases (BMs) are often resistant after initial radioiodine therapy applying the standard-activity appro

181 stimulating hormone (TSH) stimulation before radioiodine therapy can be achieved with either thyroid

182 al lesions with predicted response to (131)I radioiodine therapy can be detected.

183 cause drug-induced embryopathy in pregnancy, radioiodine therapy can exacerbate GO and surgery can re

184 eranostic compounds, with a special focus on radioiodine therapy for differentiated thyroid cancer an

185 ting agents in conjunction with TSH-promoted radioiodine therapy for epithelial thyroid cancers.

186 Delayed side effects after radioiodine therapy for hyperthyroidism are hypothyroidi

187 tiated thyroid cancer undergoing their first radioiodine therapy for remnant ablation.

188 tic thyroid carcinoma (ATC) is refractory to radioiodine therapy in part because of impaired iodine m

189 ate the delay between ICM administration and radioiodine therapy in patients with differentiated thyr

190 Radioiodine therapy is a routine procedure of treatment

191 Radioiodine therapy is generally considered after failur

192 In patients with TA or TMNG, the goal of radioiodine therapy is to achieve euthyroid status.

193 In GD, the goal of radioiodine therapy is to induce hypothyroidism, a statu

194 ion of the course of disease, and adjunctive radioiodine therapy may all be indicated as were perform

195 ptake test provides information for planning radioiodine therapy of hyperthyroidism.

196 we attempt to predict the response to (131)I radioiodine therapy of lesions additionally identified o

197 gene transfer might offer the possibility of radioiodine therapy of prostate cancer.

198 initial thyroid surgery and the addition of radioiodine therapy or external radiation therapy remain

199 Radioiodine therapy was also associated with improvement

200 In patients with papillary cancer, radioiodine therapy was associated with improvement in c

201 e primary objective was to assess whether no radioiodine therapy was noninferior to radioiodine thera

202 I PET/CT images of 47 patients scheduled for radioiodine therapy were retrospectively analyzed.

203 Radioiodine therapy with (131)I is used for treatment of

204 er no radioiodine therapy was noninferior to radioiodine therapy with respect to the absence of a com

205 hat lesions 6.5 mm with expected response to radioiodine therapy would be detectable on both systems

206 patients reached the dosimetry threshold for radioiodine therapy, including all 5 patients with NRAS

207 To maximize the effectiveness of radioiodine therapy, patients are first treated by total

208 Before and after initial radioiodine therapy, patients underwent serial PET/CT sc

209 After radioiodine therapy, patients with follicular thyroid ca

210 sue Summary 2011-01 on patient release after radioiodine therapy, there have been improvements in som

211 tastatic behavior and its reduced avidity to radioiodine therapy, warrants a tailored disease managem

212 small cohort of patients undergoing repeated radioiodine therapy, we could not demonstrate alteration

213 ose (AD) to lesions and their response after radioiodine therapy.

214 oidism and provides information for planning radioiodine therapy.

215 toms were insignificantly fewer at 1 y after radioiodine therapy.

216 with thyroid carcinoma at the first ablative radioiodine therapy.

217 ting hormone) (rTSH) to prepare patients for radioiodine therapy.

218 r patients with thyroid carcinoma undergoing radioiodine therapy.

219 e treatment response to high-activity (131)I radioiodine therapy.

220 cinoma lesions is crucial for the success of radioiodine therapy.

221 oping cancer spread that does not respond to radioiodine therapy.

222 e sufficient to preclude patients from blind radioiodine therapy.

223 as pT1a and most likely not receive adjuvant radioiodine therapy.

224 d for patients, who had undergone at least 1 radioiodine therapy.

225 d analyzed for speciation of radiocesium and radioiodine to explore their chemical behavior and isoto

226 e relative contribution of bound and unbound radioiodine to imaging findings.

227 This correlates with the distances from the radioiodine to the sugars of the corresponding bases in

228 ered 154% (P = .01) and 237% (P = .002) more radioiodine to tumor sites over control antibodies at 24

229 nal methods, BC8 delivered 2- to 4-fold more radioiodine to tumors than 1F5, with tumor-to-normal org

230 ary and follicular thyroid carcinoma, and on radioiodine total-body imaging demonstrated focal, lower

231 erations in salivary gland functioning after radioiodine treatment ((131)I) are scarce.

232 The approach of using a MEK inhibitor before radioiodine treatment could readily be translated into c

233 d cancers, and is often followed by adjuvant radioiodine treatment for papillary and follicular types

234 d sialoadenitis are frequent side effects of radioiodine treatment in differentiated thyroid cancer (

235 In most patients, radioiodine treatment is done for ablation of residual t

236 Adjuvant radioiodine treatment may be modulated, however, by surg

237 the intent to induce radioiodine uptake for radioiodine treatment of ATC.

238 ferred for a dosimetric study and subsequent radioiodine treatment of focal neck uptake of 131I were

239 We believe that the use of Thyrogen for radioiodine treatment of metastatic thyroid cancer may a

240 pectively assess the effect of high-activity radioiodine treatment on stimulated whole saliva flow ra

241 Radioiodine treatment planning for these patients is usu

242 The patient then received radioiodine treatment with granulocyte colony-stimulatin

243 ere treated with a MEK inhibitor followed by radioiodine treatment, and tumor burden was monitored by

244 After radioiodine treatment, no substantial change was seen in

245 's general condition; and know the basics of radioiodine treatment, tyrosine kinase treatment, and re

246 dysplastic syndrome more than 51 weeks after radioiodine treatment, with progression to acute leukemi

247 east cancers but at a level insufficient for radioiodine treatment.

248 ostoperative laryngoscopies and standardized radioiodine treatment.

249 The patients were followed for 1 y after radioiodine treatment.

250 e significantly impacts upon the efficacy of radioiodine treatment.

251 (AD) of radiation and response after initial radioiodine treatment.

252 -up for DTC patients receiving high-activity radioiodine treatment.

253 va were collected both before and 5 mo after radioiodine treatment.

254 rrelated with saliva flow rate changes after radioiodine treatment.

255 )I PET/CT scans before and after their first radioiodine treatment.

256 Radioactivity from radioiodine, tritium, and uranium is not expected to cre

257 by these cells allowing them to concentrate radioiodine up to 18-fold compared with controls.

258 achieve comparability between pretherapeutic radioiodine uptake (RAIU) measurements by (124)I PET/CT

259 fter exclusion of exogenous iodine overload, radioiodine uptake (RAIU) testing with (123)I or (131)I

260 T4 levels, elevated sedimentation rate, low radioiodine uptake and/or nonvisualization on scan and o

261 nfection was confirmed by immunoblotting and radioiodine uptake assays.

262 GLV-1h153 colonization of tumors mediated radioiodine uptake at potentially therapeutic doses.

263 e (PI3'K) pathways with the intent to induce radioiodine uptake for radioiodine treatment of ATC.

264 Thyrotropin stimulates radioiodine uptake for scanning in patients with thyroid

265 False-positive radioiodine uptake has been reported in many organ syste

266 iouptake assay showed a 178-fold increase of radioiodine uptake in hNIS-expressing infected cells com

267 for salivary gland dysfunction, and whether radioiodine uptake in salivary glands on diagnostic scan

268 associated with semiquantitatively assessed radioiodine uptake in salivary glands on diagnostic scan

269 Chronological changes in values for thyroid radioiodine uptake measurements (RIU) have been reported

270 Salivary gland radioiodine uptake on diagnostic scans was correlated wi

271 uccessful ablation was defined as no visible radioiodine uptake on the follow-up diagnostic scans, pe

272 at included the presence of abnormal foci of radioiodine uptake on whole-body scanning that required

273 inal diagnosis in 28 of 143 cervical foci of radioiodine uptake seen on planar imaging.

274 d on the thyroid volume to be treated and on radioiodine uptake should guide selection of the (131)I-

275 The radioiodine uptake test provides information for plannin

276 EBRT in thyroid cancer patients with reduced radioiodine uptake when a standard AA of 5.55 GBq (150 m

277 Increasing radioiodine uptake, KISS1R and TIMP1 targeting may repre

278 ing gal-3 was demonstrated in the absence of radioiodine uptake.

279 protein kinase and PI3'K pathways to induce radioiodine uptake.

280 clinical and clinical data on restoration of radioiodine uptake.

281 s were 85.0% in the group receiving low-dose radioiodine versus 88.9% in the group receiving the high

282 he metastatic lesion or lesions, therapeutic radioiodine was administered while the patient was recei

283 bination therapy with GLV-1h153 and systemic radioiodine was assessed.

284 -up strategy that did not involve the use of radioiodine was noninferior to an ablation strategy with

285 d human tumor cells efficiently concentrated radioiodine when infected with MV-NIS.

286 ual thyroid tissue after thyroidectomy using radioiodine whole-body (WB) imaging following preparatio

287 estigated a treatment strategy that combines radioiodine with external-beam radiotherapy (EBRT) for p

288 ration, prompting efforts to covalently link radioiodine with residualizing molecules.

289 f diagnosis into the antithyroid drug group, radioiodine with resolved hyperthyroidism group (radioio

290 erthyroidism group (radioiodine group A), or radioiodine with unresolved hyperthyroidism group (radio

291 yrotropin alfa was as effective as high-dose radioiodine, with a lower rate of adverse events.

292 Radioiodine within the urinary bladder or, at times, the

293 istration of the smallest possible amount of radioiodine would improve care.